[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Far Eastern Memorial Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":449},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,54,86,111,141,165,195,220,242,263,282,306,332,350,371,390,408,430],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100644275","effect-of-single-facial-acupuncture-on-dermal-structure-and-appearance-satisfaction-100644275",false,"NCT07664280","Effect of Single Facial Acupuncture on Dermal Structure and Appearance Satisfaction","Effects of Single-Session Facial Acupuncture on Dermal Structure and Aesthetic Satisfaction: A Randomized Controlled Trial Combining High-Frequency Ultrasound and Patient-Reported Outcomes","FRA","Inclusion Criteria:\n\n* Adults aged 30 to 60 years old. Individuals concerned about facial aging issues.\n* Individuals without severe chronic diseases.\n\nExclusion Criteria:\n\n* Pregnant women.\n* Individuals with coagulation disorders.\n* Individuals with a keloid constitution or tendency for abnormal scarring.\n* Individuals with acute or chronic facial hemiplegia\u002Fparalysis of any cause.\n* Individuals who have undergone facial cosmetic surgery or cosmetic injections within the past 6 months.\n* Individuals currently taking anticoagulant medications.\n* Individuals with active skin infections.\n* Individuals with a history of severe allergies.\n* Individuals otherwise deemed unsuitable for facial acupuncture by the investigators.",true,"ALL","30 Years","60 Years",{"count":22,"type":23},60,"ESTIMATED","INTERVENTIONAL",[26],"NA","This study aims to investigate the effects of a single session of facial rejuvenation acupuncture on skin structure and personal satisfaction with facial appearance. As facial aging involves complex changes in muscles, skin, and soft tissues, facial acupuncture is considered a potential minimally invasive treatment to help restore balance and promote tissue repair.\n\nResearchers will enroll 60 healthy adults aged 30 to 60 who are concerned about facial aging. Participants will be randomly assigned to either an immediate intervention group or a waitlist control group. The intervention group will receive one session of facial acupuncture at the start of the study. The control group will continue their normal daily skincare routine for 6 weeks, after which they will receive the same single acupuncture treatment.\n\nAll participants will be monitored weekly for 6 weeks. The research team will use non-invasive tools, including high-frequency skin ultrasound, 3D facial scanning, and a digital complexion analysis system, to objectively measure changes in skin thickness, facial volume, and wrinkles. Participants will also complete questionnaires at various time points to share their satisfaction with their appearance, self-confidence, and quality of life.",[29,30,31],"Facial Aging","Wrinkles","Skin Aging",[33,34,35,36,37,38,39,40],"Facial Rejuvenation Acupuncture","Acupuncture Therapy","Dermal Thickness","Skin Rejuvenation","High-Frequency Ultrasound","3D Facial Scanning","Facial Contouring","Patient Satisfaction","RECRUITING","2026-06-17",{"date":44,"type":45},"2026-06-24","ACTUAL",{"date":47,"type":45},"2026-06-11",{"date":49,"type":23},"2027-08-31",{"name":51,"class":52},"Far Eastern Memorial Hospital","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":17,"sex":18,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":65,"studyType":66,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":79,"startDateStruct":81,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100636659","maternal-methyl-nutrient-status-and-infant-neurodevelopment-study-100636659","NCT07568561","Maternal Methyl-Nutrient Status and Infant Neurodevelopment Study","Maternal Methyl-Nutrient Status During Pregnancy and Its Association With Infant Neurodevelopment: Exploring Potential Mechanisms","Inclusion Criteria for Pregnant Women\n\n* Aged 20-45 years\n* Singleton pregnancy\n* Receiving routine prenatal care at the study site and planning to deliver at Far Eastern Memorial Hospital\n\nExclusion Criteria for Pregnant Women\n\n* Diagnosed with major chronic diseases, including renal disease (defined as chronic kidney disease stage 3 or above or history of renal transplantation), liver disease (defined as liver cirrhosis or history of liver transplantation), or malignancy\n* Alcohol consumption during pregnancy\n* Diagnosed with eating disorders or psychiatric conditions that may impair the assessment of nutritional status\n\nInclusion Criteria for Newborns\n\n● Newborns delivered by mothers who participate in this study\n\nExclusion Criteria for Newborns\n\n* Diagnosed with congenital anomalies, epilepsy, or severe brain injury\n* Inability to complete neurodevelopmental assessments at 6 months, 1 year, and 2 years of age at the study site\n* Infants whose mothers are diagnosed with eating disorders or psychiatric conditions that may impair the assessment of nutritional status","0 Days","45 Years",{"count":64,"type":23},240,"2 Years","OBSERVATIONAL","This prospective cohort study examines the relationship between maternal methyl-nutrient status during pregnancy and offspring neurodevelopment. It integrates maternal dietary, biomarker, genetic, and microbiome data and follows children up to 24 months.",[69,70,71,72,73,74,75,76,77],"Infant Neurodevelopment","Nutrition","Methylation","Birth Outcomes","Pregnancy","Dietary Quality","Dietary Intake Assessment","Homocysteine","Trimethylamine N-oxide (TMAO)","2026-05-27",{"date":80,"type":45},"2026-05-29",{"date":78,"type":45},{"date":83,"type":23},"2029-01-18",{"name":51,"class":52},2,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":24,"phases":96,"briefSummary":97,"conditions":98,"keywords":100,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":78,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100639022","exploring-the-feasibility-of-transcranial-ultrasound-stimulation-in-the-treatment-of-schizophrenia-100639022","NCT07621549","Exploring the Feasibility of Transcranial Ultrasound Stimulation in the Treatment of Schizophrenia","Inclusion Criteria:\n\n1. Age: 18-65 years old.\n2. Gender: Both males and females are eligible.\n3. Diagnosed with schizophrenia according to DSM-V criteria (a PANSS total score of less than approximately 90).\n4. No changes in medication (same dosage and same drug) for at least one month.\n\nExclusion Criteria:\n\n1. History of head injury with loss of consciousness for more than 10 minutes or a history of brain surgery.\n2. Any history of epilepsy.\n3. Presence of a family history of epilepsy\n4. Heavy alcohol consumption or use of illicit drugs (substance dependence within the last 6 months or substance abuse within the last month).\n5. Any significant medical conditions that could affect normal brain function (including but not limited to stroke, CNS infections or tumors, or other major neurological diseases).\n6. Presence of a cardiac pacemaker, implanted medication pump, intracardiac lines, or acute\u002Funstable cardiac disease, as well as intracranial implants (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes) or any other metallic objects in or near the head (excluding oral metal objects)\n7. Pregnant or breastfeeding women.\n8. Presence of suicidal or self-harming tendencies\n9. Current use of medications known to lower the seizure threshold or increase the risk of suicidal behavior\n10. Presence of severe and uncontrolled systemic diseases (e.g., heart failure, liver failure, renal failure, vitamin B12 deficiency, hypothyroidism), as determined by the investigator to be unsuitable for study participation\n11. Patients with uncontrolled diabetic retinopathy accompanied by active fundus hemorrhage\n12. Concurrent participation in other clinical studies or clinical trials\n13. Presence of contraindications to the medical devices used in this study (including pulsed ultrasound, EEG, and CT), such as unheindividuals with obvious head trauma, unhealed head surgery, or significant physical or psychiatric symptoms.\n14. Any other conditions deemed unsuitable for participation in the clinical trial as assessed by the physician.","18 Years","65 Years",{"count":95,"type":23},80,[26],"1. The purpose of this study is to evaluate the safety and feasibility of transcranial ultrasound stimulation (TUS) treatment in patients with schizophrenia. Subjects are individuals diagnosed with schizophrenia who will receive non-invasive, low-intensity pulsed ultrasound stimulation targeting the hippocampus and its surrounding regions. Evaluations will be conducted before and after the treatment sessions, including electrocardiograms (ECG), blood biochemistry tests, psychiatric symptom assessments, depression level assessments, and cognitive function assessments.\n2. The primary objective is to assess the safety of this intervention in patients with schizophrenia. The secondary objective is to explore whether the current stimulation parameters may lead to improvements in the assessed symptoms. Ultimately, this study aims to support the future application of low-intensity pulsed ultrasound as a potential intervention to alleviate symptoms of schizophrenia and improve patients' quality of daily life.",[99],"Schizo Affective Disorder",[101,102,103],"scizophrenia","TUS","LIPUS",{"date":105,"type":45},"2026-06-02",{"date":107,"type":45},"2025-06-01",{"date":109,"type":23},"2028-12-31",{"name":51,"class":52},{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":18,"minAge":119,"maxAge":93,"enrollmentInfo":120,"targetDuration":4,"studyType":24,"phases":121,"briefSummary":122,"conditions":123,"keywords":125,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":85},"100601042","exploring-efficacy-of-multi-mode-cognitive-processing-therapy-cpt-for-ptsd-100601042","NCT07105345","Exploring Efficacy of Multi-Mode Cognitive Processing Therapy (CPT) for PTSD","Efficacy of Multi-Modal Cognitive Processing Therapy for PTSD: A Longitudinal, Multicenter, Single-Blind RCT on Symptoms, Sleep, Anxiety, Depression, Remission, and Posttraumatic Growth","PTSD","Inclusion Criteria:\n\n* Aged between 20 and 65 years\n* Diagnosed with PTSD according to DSM-5 criteria\n* Score ≥ 33 on the PTSD Checklist for DSM-5 (PCL-5)\n* Able to provide informed consent\n* Stable psychiatric medication regimen (if any) for at least 4 weeks prior to enrollment\n\nExclusion Criteria:\n\n* Diagnosed with schizophrenia, schizoaffective disorder, or bipolar I disorder\n* Current substance dependence or abuse within the past 6 months\n* Severe suicidal ideation or suicide attempt in the past 6 months\n* Cognitive impairment or neurological disorder affecting participation\n* Concurrent participation in other psychological treatment for PTSD","20 Years",{"count":22,"type":23},[26],"This study is a longitudinal, multicenter, single-blind, two-arm randomized controlled trial designed to evaluate the effectiveness of Multi-Modal Cognitive Processing Therapy (MMCPT) for individuals with posttraumatic stress disorder (PTSD). Participants will be randomly assigned to either the intervention group receiving MMCPT or a control group receiving treatment-as-usual (TAU). The intervention follows the standard CPT manual developed by Resick and consists of twelve weekly 90-minute individual sessions. The primary outcomes include PTSD symptom severity assessed by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). Secondary outcomes include sleep quality (actigraphy, PSQI), anxiety (STAI), depression (HDRS-17), remission rate, and posttraumatic growth (PTGI). Assessments will occur at baseline, mid-treatment, post-treatment, and at 3-, 6-, 9-, and 12-month follow-ups.",[124],"Posttraumatic Stress Disorder",[126,127,128,129,130,131,132],"Cognitive Processing Therapy","Trauma-focused therapy","Sleep quality","Anxiety","RCT","Taiwan","Depression","2026-03-18",{"date":135,"type":45},"2026-03-20",{"date":137,"type":45},"2025-09-01",{"date":139,"type":23},"2027-12-31",{"name":51,"class":52},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":148,"minAge":119,"maxAge":149,"enrollmentInfo":150,"targetDuration":4,"studyType":24,"phases":152,"briefSummary":153,"conditions":154,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":53},"100628303","effects-of-combined-upper-extremity-exercise-and-pneumatic-compression-therapy-on-breast-cancer-related-lymphedema-100628303","NCT07459881","Effects of Combined Upper Extremity Exercise and Pneumatic Compression Therapy on Breast Cancer-Related Lymphedema","Effects of Combined Upper Extremity Exercise and Pneumatic Compression Therapy on Breast Cancer-Related Lymphedema: A Prospective Single-Group Pilot Study","Inclusion Criteria:\n\n1. Female breast cancer patients aged 20-70 years\n2. Postoperative unilateral breast cancer surgery with a clinical diagnosis of lymphedema (stage I or II breast cancer treatment, with unilateral lymphedema greater than 2 cm and less than 8 cm at least one measurement point)\n3. Completion of subsequent chemotherapy\u002Fradiotherapy or other treatments at least 3 months postoperatively\n4. Ability to cooperate with 12 treatments and all assessments and sign a consent form\n\nExclusion Criteria:\n\n1. Breast cancer with a tendency for recurrence or metastasis\n2. Severe infection of the upper limb (cellulitis)\n3. Uncontrolled heart failure, deep vein thrombosis (DVT), severe peripheral vascular disease\n4. Stage III lymphedema, bilateral lymphedema, or need to take medications that may affect sweat glands in the upper limbs\n5. Other musculoskeletal disorders of the upper limbs, joint deformities, or a history of surgery\n6. Pregnancy or other conditions unsuitable for participation","FEMALE","70 Years",{"count":151,"type":23},20,[26],"Breast cancer is one of the most common cancers among women worldwide. With advances in treatment, survival rates have steadily increased; however, postoperative complications continue to affect patients' quality of life, with upper extremity lymphedema being among the most prevalent. Breast cancer related lymphedema (BCRL) can result in arm swelling, pain, restricted mobility, and psychological distress, all of which negatively impact daily functioning and social partici pation .\n\nPrevious studies have demonstrated that regular and moderate upper extremity exercise does not exacerbate lymphedema; instead, it may improve shoulder mobility, muscular strength, and contribute to edema control. In addition, therapeutic modalities such as pneumatic compression pumps and manual lymphatic drainage have been proven effective in reducing swelling and enhancing patient comfort . Recent systema tic reviews further support the beneficial effects of exercise interventions on upper limb function and quality of life in breast cancer survivors.\n\nTherefore, combining upper extremity exercise with pneumatic compression therapy may re present a promising integrative intervention to improve lymphedema and related functional limitations. This study aims to investigate the effects of such a combined approach on breast cancer patients with lymphedema by comparing outcomes across multiple ti me points, including arm circumference measurements, shoulder range of motion, upper extremity function (DASH), and quality of life (FACT B), with the goal of establishing a more comprehensive rehabilitation model.",[155],"Breast Cancer Lymphedema","NOT_YET_RECRUITING","2026-03-03",{"date":159,"type":45},"2026-03-10",{"date":161,"type":23},"2026-03",{"date":163,"type":23},"2027-12",{"name":51,"class":52},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":171,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":173,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":175,"conditions":176,"keywords":181,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":191,"completionDateStruct":193,"leadSponsor":194,"locationsCount":53},"100626136","the-air-cpr-study-ai-guided-chest-compressions-100626136","NCT07431710","The AIR-CPR Study: AI-Guided Chest Compressions","Utilizing Artificial Intelligence to Optimize Chest Compression Region During Cardio-pulmonary Resuscitation for Patients With Out-of-hospital Cardiac Arrest.","AIR-CPR","Inclusion Criteria:\n\n1. Adults aged 20 years or older.\n2. Patients with out-of-hospital cardiac arrest (OHCA) undergoing 3.cardiopulmonary resuscitation (CPR) in the emergency department.\n\nCardiac arrest caused by non-traumatic factors.\n\nExclusion Criteria:\n\n1. Pregnant patients.\n2. Patients with obvious signs of death.\n3. Patients with a signed \"Do Not Resuscitate\" (DNR) order.\n4. Patients requiring extracorporeal cardio-pulmonary resuscitation (ECPR).\n5. Patients requiring Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA).\n6. Cardiac arrest caused by massive hemorrhage, aortic emergencies, tension pneumothorax, cardiac tamponade, or pulmonary embolism.\n7. History of severe aortic valve disease or previous aortic valve surgery.\n8. Patients for whom TEE or femoral arterial catheterization is contraindicated.\n9. Situations where the medical team is unable to perform TEE or femoral arterial catheterization during CPR.",{"count":174,"type":23},255,"The AIR-CPR project aims to improve survival rates for patients with Out-of-Hospital Cardiac Arrest (OHCA) by utilizing Artificial Intelligence (AI) to optimize chest compression locations. Current guidelines recommend a standardized compression point (the lower half of the sternum), yet recent research indicates that this position can compress the aortic valve in approximately 48.7% of patients, significantly reducing the chances of successful resuscitation.\n\nThis study will develop a deep learning model based on YOLO v8 to analyze real-time arterial pressure waveforms to identify proper aortic valve opening and closing. By identifying specific waveform features that humans cannot easily distinguish, the AI will guide rescuers to adjust the compression site-typically toward the left ventricle-to ensure optimal blood output. The project seeks to transform CPR from a standardized \"one-size-fits-all\" approach into a personalized, precision medicine intervention.",[177,178,179,180],"Out-of-hospital Cardiac Arrest (OHCA)","Cardiopulmonary Resuscitation (CPR)","Aortic Valve Compression","Precision Resuscitation",[182,183,184,185,186,187],"Artificial Intelligence","Transesophageal Echocardiography","Arterial Pressure Waveform","Chest Compression Location","Personalized Resuscitation","Hemodynamic Monitoring","2026-02-19",{"date":190,"type":45},"2026-02-24",{"date":192,"type":45},"2025-01-06",{"date":139,"type":23},{"name":51,"class":52},{"id":196,"slug":197,"hasResults":11,"nctId":198,"briefTitle":199,"officialTitle":199,"acronym":4,"eligibilityCriteria":200,"healthyVolunteers":17,"sex":148,"minAge":4,"maxAge":4,"enrollmentInfo":201,"targetDuration":203,"studyType":66,"phases":4,"briefSummary":204,"conditions":205,"keywords":209,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":85},"100622619","the-role-of-blood-perfusion-in-cervical-cancer-cervical-intraepithelial-neoplasm-and-ovarian-cancer-patients-100622619","NCT07385976","The Role of Blood Perfusion in Cervical Cancer, Cervical Intraepithelial Neoplasm and Ovarian Cancer Patients","Inclusion Criteria:\n\n* Regarding the topic \"Hemoperfusion characteristics of cervical cancer and precancerous lesions, and the correlation between hemoperfusion and prognosis\":\n\n  1. Adult women who have had a normal cervical smear within the past three years and have no other gynecological cancers (control group).\n  2. Adult women with cervical cancer or precancerous lesions.\n* Regarding the topic \"Correlation between hemoperfusion and prognosis of ovarian cancer\":\n\n  1. Adult women suspected of having ovarian cancer, fallopian tube cancer, or peritoneal cancer before surgery.\n\nExclusion Criteria:\n\n* Regarding the topic \"Hemoperfusion characteristics of cervical cancer and precancerous lesions of the cervix, and the correlation between hemoperfusion and prognosis\":\n\n  1\\. Patients who cannot cooperate with vaginal 3D ultrasound scans.\n* Regarding the topic \"Correlation between hemoperfusion and prognosis of ovarian cancer\":\n\n  1. Patients who cannot cooperate with vaginal or abdominal 3D ultrasound scans.",{"count":202,"type":23},100,"3 Months","This study will elucidate the role of 3D transvaginal ultrasound in assessing (1) cervical vascularity and blood flow in patients with cervical cancer and cervical intraepithelial neoplasm, and (2) tumor vascularity and blood flow in patients with ovarian cancer.",[206,207,208],"Cervical Cancer","Cervical Intraepithelial Neoplasm","Ovarian Cancer",[210,211],"3D power Doppler sonography","cervical vascularization and blood flow","2026-01-27",{"date":214,"type":45},"2026-02-04",{"date":216,"type":23},"2026-01-19",{"date":218,"type":23},"2030-12-31",{"name":51,"class":52},{"id":221,"slug":222,"hasResults":11,"nctId":223,"briefTitle":224,"officialTitle":225,"acronym":4,"eligibilityCriteria":226,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":227,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":229,"conditions":230,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":234,"lastUpdatePostDateStruct":235,"startDateStruct":237,"completionDateStruct":239,"leadSponsor":241,"locationsCount":53},"100601427","clinical-outcomes-of-non-indicated-staged-laparotomies-in-abdominal-trauma-100601427","NCT07110350","Clinical Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma","Clinical Characteristics and Outcomes of Non-Indicated Staged Laparotomies in Abdominal Trauma Patients: A Single-Center Retrospective Study","Inclusion Criteria:\n\n* This study included patients with abdominal trauma who were admitted to Far Eastern Memorial Hospital and received exploratory laparotomy between January 1, 2013, and December 31, 2024.\n\nExclusion Criteria:\n\n* Patients who experienced cardiac arrest prior to hospital arrival (OHCA) or in-hospital cardiac arrest (IHCA).\n* Patients with an Abbreviated Injury Scale (AIS) score ≥ 4 in any body region other than the abdomen.\n* Patients who died within 24 hours after the most recent surgical procedure.",{"count":228,"type":23},350,"The goal of this observational study is to understand how often staged operations are performed in abdominal trauma patients without meeting standard clinical criteria, and to explore related clinical characteristics and outcomes. The main questions it aims to answer are:\n\nHow frequently are staged operations performed when not clinically indicated?\n\nWhat are the clinical features and outcomes of patients who undergo non-indicated staged operations?\n\nWhat are the risk factors for delayed reoperation among patients who initially received a single operation?\n\nResearchers will review medical records of patients who underwent exploratory laparotomy for abdominal trauma at Far Eastern Memorial Hospital between January 1, 2013, and December 31, 2024. Participants will be grouped based on whether they had a single or staged operation, and whether their initial operation met established criteria for a staged approach. Clinical characteristics and outcomes will be compared across groups.",[231,232,233],"Abdominal Trauma","Damage Control Surgery","Laparotomy","2025-08-05",{"date":236,"type":45},"2025-08-07",{"date":238,"type":23},"2025-08-15",{"date":240,"type":23},"2025-11-30",{"name":51,"class":52},{"id":243,"slug":244,"hasResults":11,"nctId":245,"briefTitle":246,"officialTitle":51,"acronym":4,"eligibilityCriteria":247,"healthyVolunteers":11,"sex":148,"minAge":92,"maxAge":4,"enrollmentInfo":248,"targetDuration":4,"studyType":24,"phases":250,"briefSummary":252,"conditions":253,"keywords":255,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":262,"locationsCount":53},"100601757","phase-3-the-effect-of-nighttime-mirabegron-solifenacin-tolterodine-or-oxybutynin-on-nocturia-sexual-function-autonomic-function-and-lower-urinary-tract-blood-flow-perfusion-in-women-with-overactive-bladder-syndrome-randomized-controlled-trial-100601757","NCT07114640","The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","Inclusion Criteria:\n\n* \\>18 years old.\n* female patients with overactive bladder syndrome\n\nExclusion Criteria:\n\n* Clinically significant dysuria (inability to urinate, difficulty urinating).\n* Severe stress urinary incontinence (urinary incontinence caused by coughing).\n* Mixed urinary incontinence mainly caused by stress urinary incontinence (urinary incontinence caused by coughing as the main symptom).\n* Contraindications to antimuscarinic drugs or adrenergic receptor agonists.",{"count":249,"type":23},220,[251],"PHASE3","The optimal medication for women with nocturia remains uncertain. This clinical trial aimed to determine the most effective medication for women with overactive bladder and nocturia. Its primary objectives were to answer the following questions:\n\nWhich medication is most effective for women with nocturia? Which medication has the least effect on heart rate variability in women with nocturia?",[254],"Urinary Bladder, Overactive",[256],"autonomic nerve system, nocturia, psychologic distress, sexual function, bladder blood perfusion, heart rate variability, overactive bladder syndrome","2025-08-04",{"date":259,"type":45},"2025-08-11",{"date":236,"type":23},{"date":109,"type":23},{"name":51,"class":52},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":11,"sex":148,"minAge":4,"maxAge":4,"enrollmentInfo":269,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":271,"conditions":272,"keywords":274,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":277,"startDateStruct":278,"completionDateStruct":279,"leadSponsor":281,"locationsCount":53},"100601758","the-role-of-pole-mutation-in-high-risk-endometrial-cancer-100601758","NCT07114653","The Role of POLE Mutation in High Risk Endometrial Cancer.","Inclusion Criteria:\n\n* women with high-risk for recurrent endometrial cancer\n\nExclusion Criteria:\n\n* Nil",{"count":270,"type":23},150,"The actual role of POLE mutations in high-risk endometrial cancer is undetermined. The main question it aims to answer is:\n\nWhat is the prevalence of POLE mutations in high-risk endometrial cancer case? What is the impact of POLE mutations in real world high-risk endometrial cancer case?",[273],"Endometrial Neoplasms",[275,276],"Endometrial cancer","POLE mutation",{"date":259,"type":45},{"date":137,"type":23},{"date":280,"type":23},"2026-12-31",{"name":51,"class":52},{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":17,"sex":18,"minAge":92,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":292,"conditions":293,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":53},"100601211","exploring-the-relationship-between-mini-clinical-evaluation-exercise-mini-cex-and-entrustable-professional-activities-epas-in-occupational-therapy-clinical-interns-independent-competence-100601211","NCT07107542","Exploring the Relationship Between Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities (EPAs) in Occupational Therapy Clinical Interns' Independent Competence","Entrustable Professional Activities and Mini-Clinical Evaluation Exercise in a Simulated Workplace-based Assessment for Physical Occupational Therapist Intern","Inclusion Criteria:\n\n* Occupational therapy interns in the physical domain at Far Eastern Memorial Hospital\n* Provide informed consent to participate\n\nExclusion Criteria:\n\n* None specified","35 Years",{"count":291,"type":23},50,"The goal of this observational cross-sectional study is to evaluate whether the combined use of Mini-Clinical Evaluation Exercise (Mini-CEX) and Entrustable Professional Activities (EPAs) can assess the independent clinical competence of occupational therapy interns at Far Eastern Memorial Hospital. The main questions it aims to answer are:\n\n1. Does the performance on Mini-CEX correlate with the interns' ability to perform independently?\n2. Does the use of EPAs provide additional insight into interns' readiness for unsupervised clinical practice?\n\nParticipants will:\n\n1. Provide informed consent at the sixth week of their internship.\n2. Undergo assessment with Mini-CEX and EPAs during their eighth week of clinical training.\n3. Complete demographic questionnaires including age, gender, study habits, prior university experience, parental occupation, and residence area.",[294,295,296,297],"Entrustable Professional Activities","Mini-clinical Evaluation Exercise","Physical Occupational Therapy","Occupational Therapy Education","2025-07-30",{"date":300,"type":45},"2025-08-06",{"date":302,"type":23},"2025-10-08",{"date":304,"type":23},"2029-03-30",{"name":51,"class":52},{"id":307,"slug":308,"hasResults":11,"nctId":309,"briefTitle":310,"officialTitle":311,"acronym":4,"eligibilityCriteria":312,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":4,"enrollmentInfo":313,"targetDuration":4,"studyType":24,"phases":315,"briefSummary":316,"conditions":317,"keywords":321,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":325,"lastUpdatePostDateStruct":326,"startDateStruct":328,"completionDateStruct":330,"leadSponsor":331,"locationsCount":4},"100593373","early-speaking-valve-in-ventilator-weaning-effects-on-communication-depression-and-quality-of-life-100593373","NCT07005596","Early Speaking Valve in Ventilator Weaning: Effects on Communication, Depression, and Quality of Life","Assessing the Impact of Early Tracheostomy Speaking Valve Intervention on Communication, Depression, and Quality of Life in Long-term Ventilator-dependent Patients During the Weaning Phase","Inclusion Criteria:\n\n* Age: ≥18 years old\n* Consciousness: Glasgow Coma Scale (GCS) score 13-15 (can voluntarily open eyes or respond when called, able to follow instructions to move)\n* Tracheostomy: Performed ≥24 hours, with no bleeding, pain, subcutaneous emphysema, pneumothorax, or infection\n* Ventilator Weaning: Trained according to the hospital's Respiratory Care Center standards, able to undergo spontaneous breathing training during the day\n* Ventilator Settings: FiO2 ≤40%\n* Vital Signs: Stable:\n* Heart rate 60-100 beats\u002Fmin\n* Respiratory rate 12-20 breaths\u002Fmin\n* Systolic blood pressure \\\u003C150 mmHg, diastolic blood pressure \\\u003C90 mmHg\n* Blood oxygen saturation 95-100%, no dyspnea complaints\n* Richmond Agitation-Sedation Scale (RASS) between -1 and +1\n* Language: Able to communicate in Mandarin, Taiwanese, or Hakka\n* Consent: Willing to participate in the study\n\nExclusion Criteria:\n\n* Recent surgery, anesthesia, or sedative use affecting consciousness\n* Severe unstable vital signs or inability to breathe normally\n* Upper airway obstruction or vocal cord paralysis\n* High dependence on ventilators or high-concentration oxygen therapy\n* History of depression or currently taking antidepressant medication",{"count":314,"type":23},70,[26],"This study evaluates the impact of early tracheostomy speaking valve intervention on communication ability, depression levels, and quality of life in ventilator-dependent patients during the weaning phase. Participants will be randomly assigned to either an experimental group using the Passy-Muir speaking valve or a control group employing standard non-verbal communication methods. Structured questionnaires will be used at multiple time points to assess changes in patient outcomes. The study aims to provide evidence supporting the use of speaking valves to enhance communication and emotional well-being in tracheostomy patients, potentially improving recovery and care strategies.",[318,319,132,320],"Respiratory Failure","Communication Disorders","Quality of Life",[322,323,324],"speaking valve","tracheostomy","communication","2025-06-04",{"date":327,"type":45},"2025-06-05",{"date":329,"type":23},"2025-06-15",{"date":139,"type":23},{"name":51,"class":52},{"id":333,"slug":334,"hasResults":11,"nctId":335,"briefTitle":336,"officialTitle":337,"acronym":4,"eligibilityCriteria":338,"healthyVolunteers":11,"sex":148,"minAge":119,"maxAge":4,"enrollmentInfo":339,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":340,"conditions":341,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":342,"lastUpdatePostDateStruct":343,"startDateStruct":345,"completionDateStruct":347,"leadSponsor":349,"locationsCount":53},"100557224","intraperitoneal-chemotherapy-in-recurrent-ovarian-cancer-100557224","NCT06535334","Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","Intravenous Chemotherapy Versus Intraperitoneal Chemotherapy in Recurrent Ovarian Cancer","Inclusion Criteria:\n\n* women who had recurrent ovarian cancer and was treated with either intravenous or intraperitoneal platinum based chemotherapy\n\nExclusion Criteria:\n\n* women who did not complete the designated treatment course (exception to those who had to quit due to progressive disease or death of any cause)",{"count":95,"type":23},"This study aims to compare intravenous chemotherapy versus intraperitoneal chemotherapy in patients with recurrent ovarian cancer.",[337],"2024-07-31",{"date":344,"type":45},"2024-08-02",{"date":346,"type":23},"2024-08-15",{"date":348,"type":23},"2026-05",{"name":51,"class":52},{"id":351,"slug":352,"hasResults":11,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":11,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":357,"targetDuration":359,"studyType":66,"phases":4,"briefSummary":360,"conditions":361,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":370,"locationsCount":53},"100484870","a-multi-center-cardiac-pyp-scan-registry-in-taiwan-100484870","NCT05593679","A Multi-center Cardiac PYP Scan Registry in Taiwan","A Multi-center Registry for Clinical Information and 99mTc-pyrophosphate Scintigraphy in Patients With Suspected Cardiac Amyloidosis in Taiwan","Inclusion Criteria:\n\n1. ≥ 20 years of age\n2. Documented diagnosis or r\u002Fo of ATTR amyloidosis\n\nExclusion Criteria:\n\n1. Pregnant or nursing (lactating) women.\n2. Important systemic diseases (except heart disease or neurological diseases) such as liver cirrhosis, active malignant tumors, etc., with a life expectancy of less than 6 months.\n3. Patient who refused clinical follow up.",{"count":358,"type":23},1000,"1 Year","Amyloid deposition in the heart is called cardiac amyloidosis (CA); 95% is immunoglobulin light chain amyloidosis (AL) and transthyretin amyloidosis (ATTR). Hereditary (ATTRm) or wild-type (ATTRwt) depends on whether the ATTRm gene is mutated or not. The most common mutation in Taiwan is A97S, 80% have left ventricular hypertrophy. The good prognosis depends on early diagnosis and correct treatment strategy.\n\nBone-avid tracers such as 99mTc-PYP\u002FDPD\u002FHMDP could detect CA. The mechanism is not clear yet, which may be related to the microcalcification. AL amyloidosis is mostly between visual score grade 0-2, and ATTR-CM is usually grade≥2 on PYP scan, or heart to contralateral (H\u002FCL) ratio, and it might replace invasive myocardial biopsy. However, there are no large-scale clinical studies, lack of standardization data, and limited information in comparison between clinical and imaging parameters.\n\nThe project will enroll patients with suspected or diagnosed with CA according to CA diagnostic algorithm. Clinical data and image parameters are collected and compared. The project aims to set up prediction models based on the multi-parameters of PYP scan using artificial intelligence technology, including imaging registration and alignment technology, and standardization. The investigators further use the key cardiovascular data elements and imaging-derived database using model training network to extract image features to develop the diagnostic and prognostic prediction models, which are expected to validate the clinical significance and improve patient-centric performance and efficient clinical decision making.",[362,363],"Heart Failure","Cardiac Amyloidosis","2024-07-25",{"date":366,"type":45},"2024-07-29",{"date":368,"type":45},"2022-11-01",{"date":139,"type":23},{"name":51,"class":52},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":375,"acronym":4,"eligibilityCriteria":376,"healthyVolunteers":11,"sex":18,"minAge":119,"maxAge":4,"enrollmentInfo":377,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":379,"conditions":380,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":382,"lastUpdatePostDateStruct":383,"startDateStruct":385,"completionDateStruct":387,"leadSponsor":389,"locationsCount":53},"100545428","taiwan-registry-of-hypertrophic-cardiomyopathy-thic-research-synopsis-100545428","NCT06381778","Taiwan Registry of Hypertrophic Cardiomyopathy (THIC) Research Synopsis","Inclusion Criteria:\n\n1. Presence of left ventricular hypertrophy (LVH) on echo\u002FCMRI:\n2. maximal interventricular septal (IVST) and\u002For posterior wall thickness (PWT) ≥13 mm,\n3. apical wall thickness ≥15 mm or a ratio of apical to basal LV wall thickness of ≥ 1.3 at end-diastole, OR\n4. maximal LV wall thickness ≥ 15mm of ANY OTHER PART\n5. Male and female adult age ≥ 20 year-old\n6. Patients willing to comply with and sign the informed consent\n\nExclusion Criteria:\n\n1. Patients refuse or unable to give informed consent\n2. Patients unlikely to comply with the protocol or unable to understand the nature and possible consequences of the program\n3. Co-arctation of the aorta, severe aortic stenosis, or severe LV pressure overload\n4. Athletic heart\n5. Non-compaction cardiomyopathy",{"count":378,"type":23},2600,"Hypertrophic cardiomyopathy (HCM) is hallmarked by the presence of left ventricular hypertrophy (LVH) and may present various symptoms including arrhythmia and heart failure. Mutations in the genes related to sarcomeric proteins and metabolic disorders are known causes of HCM. However, it remains required to further explore the prevalence of HCM in the context of Taiwanese' genetic background. Additionally, certain rare diseases that affect the heart, including Fabry disease, cardiac amyloidosis, may present LVH, which makes precise diagnosis among HCM and these diseases more challenging. In this TSOC multi-center registry, we aim to systematically evaluate the clinical, genetic, biochemical features,prevalence, and possible natural course of HCM and relevant rare diseases such as Fabry disease in Taiwan. In the meanwhile, we may also generate the specific \"red-flag\" signs of Fabry disease in Taiwan.",[381],"Hypertrophic Cardiomyopathy","2024-07-24",{"date":384,"type":45},"2024-07-26",{"date":386,"type":45},"2023-02-06",{"date":388,"type":23},"2027-12-01",{"name":51,"class":52},{"id":391,"slug":392,"hasResults":11,"nctId":393,"briefTitle":394,"officialTitle":395,"acronym":4,"eligibilityCriteria":396,"healthyVolunteers":11,"sex":148,"minAge":119,"maxAge":4,"enrollmentInfo":397,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":398,"conditions":399,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":407,"locationsCount":53},"100460776","hrt-on-overactive-bladder-symptoms-sexual-function-depressive-symptoms-autonomic-function-and-arterial-stiffness-100460776","NCT05280028","HRT on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness","The Impact of Different Hormone Therapy Regimens on Overactive Bladder Symptoms, Sexual Function, Depressive Symptoms, Autonomic Function, and Arterial Stiffness","Inclusion Criteria:\n\n* \\>20 years old female\n* Menopausal symptoms, still have a uterus, and no breast or other cancers, and no vascular-blocking disease such as stroke.\n\nExclusion Criteria:\n\n* Nil.",{"count":202,"type":23},"Therefore, the aim of this study is to assess the therapeutic effect on overactive bladder symptoms, sexual function, heart rate variability, arterial stiffness, atherosclerosis, sleep, and depression between tibolone and E2V\u002FMPA.\n\nFrom the results, the investigators will compare the effect of tibolone versus E2V\u002FMPA on overactive bladder symptoms, sexual function, autonomic function, arterial stiffness, atherosclerosis, sleep and depression.",[400],"Menopausal Syndrome","2024-06-13",{"date":403,"type":45},"2024-06-17",{"date":405,"type":45},"2022-02-07",{"date":280,"type":23},{"name":51,"class":52},{"id":409,"slug":410,"hasResults":11,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":11,"sex":18,"minAge":92,"maxAge":415,"enrollmentInfo":416,"targetDuration":4,"studyType":24,"phases":418,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":156,"whyStopped":4,"lastUpdateSubmitDate":422,"lastUpdatePostDateStruct":423,"startDateStruct":425,"completionDateStruct":427,"leadSponsor":429,"locationsCount":4},"100524236","anti-reflux-mucosal-ablation-therapy-randomized-sham-control-trial-for-gastroesophageal-reflux-disease-100524236","NCT06106100","Anti-reflux Mucosal Ablation Therapy Randomized Sham Control Trial for Gastroesophageal Reflux Disease","Efficacy and Safety of Endoscopic Anti-reflux Mucosal Ablation Therapy for Gastroesophageal Reflux Disease: a Single Blind Randomized Sham Controlled Trial","Inclusion Criteria:\n\n* Adults aged over 18 years old\n* History of GERD for over 6 months, who had received PPIs for over 6 months but still had symptoms of typical GERD symptoms (GERD-HRQL score of \\>8, acid reflux sensation or heartburn), and\u002For other symptoms as lump throat, night cough, acid related chest tightness (without other possible explanation of these symptoms)\n* Acid exposure time \\> 6%\n* DeMeester score ≥ 14.72\n\nExclusion Criteria:\n\n* Pregnancy\n* BMI\\>=35\n* Hiatal hernia \\> 2cm or Flap Valve Hill grade III\u002FIV\n* GERD LA grade C\u002FD or esophageal ulcer\n* Abnormal anatomy of esophagus (esophagectomy, stricture, diverticulum)\n* Barrett's esophagus with dysplasia\n* Esophageal motility disorders\n* History of gastroparesis\n* Cirrhosis\n* Esophageal and gastric varices\n* Previous gastric surgery and anti-reflux procedures\n* History of scleroderma or dermatomyositis\n* Coagulation disorders (Bleeding tendency and coagulopathy)\n* History of oncological disease (not active within 2 years)","75 Years",{"count":417,"type":23},68,[26],"The goal of this randomized clinical trial is to investigate the efficacy and safety of antireflux mucosal ablation (ARMA) for patients with refractory gastroesophageal reflux disease (GERD). The trial aim to evaluate :\n\n* Efficacy of ARMA comparing with medical treatment alone (proton pump inhibitor (PPI)), using GERD-Health Related Quality of Life Questionnaire (GERD- HRQL questionnaire), improvement of acid exposure time and DeMeester score\n* Safety and complications of ARMA Participants will be randomly divided into 2 groups. The intervention group will be undergone ARMA, and the control group will be undergone sham endoscopic treatment.\n\nThe primary endpoint will be symptoms relief (GERD-HRQL decreases \\> 50%). The secondary endpoint will be dosage adjustment of PPI, complications, improvement of acid exposure time and DeMeester score.",[421],"Gastroesophageal Reflux Disease","2024-02-21",{"date":424,"type":45},"2024-02-23",{"date":426,"type":23},"2024-03",{"date":428,"type":23},"2027-10",{"name":51,"class":52},{"id":431,"slug":432,"hasResults":11,"nctId":433,"briefTitle":434,"officialTitle":434,"acronym":4,"eligibilityCriteria":435,"healthyVolunteers":11,"sex":148,"minAge":119,"maxAge":4,"enrollmentInfo":436,"targetDuration":4,"studyType":66,"phases":4,"briefSummary":438,"conditions":439,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":441,"lastUpdatePostDateStruct":442,"startDateStruct":444,"completionDateStruct":446,"leadSponsor":448,"locationsCount":53},"100441946","the-role-of-endometrial-blood-flow-in-endometrial-cancer-100441946","NCT05034991","The Role of Endometrial Blood Flow in Endometrial Cancer","Inclusion Criteria:\n\n\\- \\>20 years old female had Endometrial cancer\n\nExclusion Criteria:\n\n\\- \\\u003C20 years old female",{"count":437,"type":23},75,"The incidence of endometrial cancer is gradually increasing nowaday. Sonography can be used to evaluate the endometrial volume, the vascularity and the blood flow. This study will analyze the role of preoperative endometrial blood flow in the outcome of endometrial cancer patients.",[440],"Endometrial Cancer","2023-03-27",{"date":443,"type":45},"2023-03-29",{"date":445,"type":45},"2021-01-05",{"date":447,"type":23},"2029-12-31",{"name":51,"class":52},""]